Meta-analysis of randomised trials comparing thiopurines in childhood acute lymphoblastic leukaemia

G. Escherich, S. Richards, L. C. Stork, A. J. Vora

Research output: Contribution to journalArticle

27 Scopus citations

Abstract

Mercaptopurine has been used in continuing treatment of childhood acute lymphoblastic leukaemia since the mid 1950s. Recent advances in the understanding of thiopurine pharmacology indicated that thioguanine (TG) might be more effective than mercaptopurine (MP). The US and UK cooperative groups began randomised thiopurine trials and agreed prospectively to a meta-analysis. All randomised trials of TG versus MP were sought, and data on individual patients were analysed by standard methods. Combining three trials (from US, UK and Germany), the overall event-free survival (EFS) was not significantly improved with TG (odds ratio (OR)=0.89; 95% confidence interval 0.78-1.03). Apparent differences in results between trials may be partly explained by the different types of patients studied. The larger treatment effect reported in males in the US trial was confirmed in the other trials. There was heterogeneity between sex/age subgroups (P=0.001), with significant EFS benefit of TG only observed for males aged<10 years old (OR=0.70; 0.58-0.84), although this did not result in a significant difference in overall survival (OR=0.83; 0.62-1.10). Additional toxicity occurs with TG. Mercaptopurine remains the standard thiopurine of choice, but further study of TG may be warranted to determine whether it could benefit particular subgroups.

Original languageEnglish (US)
Pages (from-to)953-959
Number of pages7
JournalLeukemia
Volume25
Issue number6
DOIs
StatePublished - Jun 1 2011

    Fingerprint

Keywords

  • childhood
  • mercaptopurine
  • systematic review
  • thioguanine
  • thiopurine

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this